Effectiveness of PCR primers for the detection of occult hepatitis B virus infection in Mexican patients

Francisca Sosa-Jurado, Daniel Meléndez-Mena, Nora H. Rosas-Murrieta, Belinda Guzmán-Flores, Miguel A. Mendoza-Torres, Roberto Barcenas-Villalobos, Luis Márquez-Domínguez, Paulina Cortés-Hernández, Julio Reyes-Leyva, Verónica Vallejo-Ruiz, Gerardo Santos-López

1 Laboratorio de Biología Molecular y Virología, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Atlixco, Puebla, México, 2 Servicio de Gastroenterología, Unidad Médica de Alta Especialidad, Centro Médico Nacional "General de División Manuel Ávila Camacho", Instituto Mexicano del Seguro Social, Puebla, México, 3 Centro de Química, Instituto de Ciencias, Benemérita Universidad Autónoma de Puebla, Puebla, México, 4 Banco de Sangre, Unidad Médica de Alta Especialidad, Centro Médico Nacional "General de División Manuel Ávila Camacho", Instituto Mexicano del Seguro Social, Puebla, México, 5 Laboratorio de Biología Celular, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Atlixco, Puebla, México

Abstract

Background

Occult hepatitis B infection (OBI) is defined as the presence of hepatitis B virus (HVB) DNA in the liver of HBsAg negative individuals with or without detectable viral DNA in serum. OBI is a diagnostic challenge as it is characterized by a very low viral load, intermittently detectable through time. Individuals with OBI can develop chronic hepatic disease, including liver cirrhosis and hepatocellular carcinoma. The aim of this work was to produce tools to improve OBI detection of the HVB genotypes prevalent in Mexico.

Methods

We designed and tested primers to detect OBI in serum samples by nested and real-time PCR. Conserved sites in the viral genome were determined by alignment of the most frequent HBV genotypes in Mexico (H, G/H, F and D) and primers spanning the entire viral genome were designed for first round and nested PCR. Primers were tested in serum samples of 45 patients not co-infected with hepatitis C virus or with HIV, out of a group of 116 HBsAg (-)/anti-HBc (+) individuals. Primers were also tested in a control group with chronic HBV. Nested PCR products obtained from HBsAg (-)/anti-HBc (+) were sequenced and used to design primers for real-time PCR (SYBR Green).

Results

The most effective primer pairs to detect HBV products by nested PCR targeted ORF regions: PreS2/P, S/P, X/PreC, and C; while by real-time PCR they targeted ORF regions PreS2/P, S/P, X, and C. Out of the 45 HBsAg (-)/anti-HBc (+) patients tested, the viral...
genome was detected in 28 (62.2%) and 34 (75.5%), with nPCR and real-time PCR respectively.

Conclusion

Primers designed for real-time PCR detected up to 75.5% of suspected OBI Mexican patients, with or without liver disease, which represents an improvement from previous PCR strategies.

Introduction

Hepatitis B virus (HBV) is the most prevalent and dangerous infectious agent among those that produce hepatic disease in humans [1]. The main serologic markers used for screening in transfusion medicine are the surface antigen (HBsAg) and specific antibodies against the core protein (anti-HBc); however, for a more effective diagnosis the e-antigen (HBeAg), anti-HBsAg (anti-HBs) and viral DNA detection may be included [2]. Occult hepatitis B virus infection (OBI) is defined as the presence of HBV DNA in the liver (with or without detectable HBV DNA in serum) in HBsAg negative individuals [3] and it is the most complex to diagnose HBV infection [4].

Even though manufacturers have improved commercial HBsAg detection assays to include the most prevalent HBsAg mutants and to increase sensitivity [5–7], failures in diagnosis due to amino acid changes in HBsAg still occur. Mutations in the so-called "a" determinant at the center of the S ORF or in adjacent regions have been related to the escape from antibodies generated by natural infection or by vaccination and are involved in HBV diagnostic failures [8–10]. The viral DNA in occult hepatitis B virus infection is able to replicate, transcribe and synthesize proteins at very low levels and this infection may lead to the development of severe forms of liver disease [11].

Currently there is no standard assay for OBI diagnosis in liver tissue or serum and the only consistent method is the detection of viral DNA by real-time PCR or nested PCR (nPCR). Real-time PCR gives better results than nested PCR, but both techniques depend on the annealing capacity of specific primers on the circulating HBV genotypes [3]. The detection of both HBsAg and viral DNA is a diagnostic challenge of particular relevance for OBI diagnosis. In the present study, we determined the efficacy of primer sets designed to anneal in different sites of the viral genome to amplify diverse segments along the HBV genome. These primers were used to detect viral DNA in HBsAg (-)/anti-HBc (+) patients.

Material and methods

Patients

The study was carried out in accordance with the Declaration of Helsinki and in accordance with ethical regulations approved by the institutional ethics committee (Comité Local de Investigación en salud 2101 IMSS; study number R-2010-2101-31). Patients were invited to participate at the Gastroenterology Service of the National Health Centre, Manuel Avila Camacho, Instituto Mexicano del Seguro Social (IMSS) in Puebla City, Mexico. A total of 116 HBsAg (-)/anti-HBc (+) patients were identified in the Gastroenterology Service between June 2013 and December 2015. Among these, patients with the following criteria were included in the study: female or male, >18 years old, with at least three similar previous HBsAg (-)/anti-HBc (+) results in the last 5 years, not co-infected with HCV or with HIV, no history of
treatment for HBV, HCV or HIV, not transplanted or transfused in the last 10 years, willing to participate and to sign a written informed consent letter.

For the analysis, we considered as occult hepatitis B patients the HBsAg (-) subjects with HBV DNA detected in at least three different viral genomic regions, using nested PCR or real-time PCR and with at least one amplicon confirmed by Sanger sequencing.

Control group
Serum samples of 8 blood donors (BD) HBsAg (+)/anti-HBc (+)/HBV DNA (+), not coinfected with HCV and/or HIV were included as positive HBV controls. Additionally, two blood donors that were HBsAg (-)/anti-HBc (+)/HBV DNA (+) and HBsAg (-)/anti-HBc (-)/HBV DNA (+), were included and analyzed along the controls.

Detection of serological markers
All serum samples of patients and controls were analyzed for HBsAg, anti-HBc, anti-HCV and anti-HIV/Agp24 serological markers, using a chemiluminescent microparticle immunoassay (CMIA, Abbot Laboratories Diagnostics Division, Abbott Park, IL, USA). All HBsAg (-)/anti-HBc (+) sera were further explored for detection of HBeAg (EIA 3890) and Anti-HBeAg (EIA 3891) by Enzyme Immunoassay (EIA; DRG International Inc., Springfield, NJ, USA).

Automated detection of viral nucleic acids
Samples of blood donors were analyzed for detection of HIV-1 RNA, HCV RNA, and HBV DNA by the Procleix Ultro Plus System (Gen-Probe Incorporated, San Diego, CA, USA), that screens for the genetic material of all three viruses simultaneously. The particular viruses present in screened samples (HIV-1, HCV, and/or HBV) were further detected by the Procleix Ultro Plus Discriminatory Assays (Gen-Probe Incorporated, San Diego, CA, USA). All control individuals included in this study had HBV DNA detectable by the Procleix Ultro Plus System, except the blood donor that was HBsAg (-)/anti-HBc (+), who was negative in Procleix assays and was identified as HBV DNA(+) by PCR (as described below).

Primer design for PCR assays
Primer pairs to amplify fragments of the hepatitis B genome covering the PreS1, PreS2, S, P, X, PreC and Core regions, were designed with Primer 3 v.0.4.0 software (http://bioinfo.ut.ee/primer3-0.4.0/) [12]. The conserved sites in these regions were determined by alignment of complete genome sequences of the most frequent genotypes in Mexico, (ClustalW2, https://www.ebi.ac.uk/Tools/msa/clustalw2/help/faq.html) which are mainly H and G/H; but some D and F have also been reported in relation to occult hepatitis B virus cases.

We predicted amplicons ranging between 454 and 1158 bp in first round (1R) PCRs, while one or more amplicons ranging between 236–644 bp were predicted for second round PCR (nested PCR). Primers for real-time PCR (SYBR Green) were designed considering the HBV sequences obtained from nested PCR in this work, using Primer Quest Tool software (Integrated DNA Technologies Inc., Commercial Park Coralville, IA 52241, USA) [13]. All primers were synthesized by Integrated DNA Technologies Inc. Primer sequences are described in S1 Table.

DNA extraction
Total DNA in serum samples (1 ml) was obtained using the QIAamp UltraSens Virus Kit (Qia-gen, Hilden, Germany) according to manufacturer’s instructions. The sample from the blood donor in the control group (HBsAg (-)/anti-HBc (+)) that by the Procleix system had
undetectable HBV DNA (BDOBI), was first concentrated by polyethylene glycol precipitation [14] and the pellet was resuspended in HEPES-Tris / imidazole pH7.4 buffer, before DNA extraction with the kit.

**PCR standardization**

A gradient thermocycler (PTC-200, MJ Research, Waltham, MA, USA) was used to obtain the optimal amplification conditions for each primer pair. Seven products of first round (1R) PCR (S1 Table) were used for the subsequent nested PCR reactions. The annealing temperature ranged from 45˚C to 68˚C, denaturation was at 95˚C and extension at 72˚C. PCR Master Mix (Promega, Madison, WI, USA) was used to perform both the first and nested PCRs using primers at 200 nM. Eight options to perform the nested PCR were designed and are shown in S1 Table. PCR products were visualized by 1% agarose gel electrophoresis with ethidium bromide. The Procleix Ultrio Tigris System and Cobas Amplicor DNA HBV (Roche Diagnostic, IN, USA) negative controls, as well as distilled water were included as quality controls in PCR.

**Cloning and sequencing of PCR products**

The PCR products were cloned into the pJET1.2/blunt Cloning Vector (CloneJET PCR Cloning Kit, Thermo Scientific Inc) according to the manufacturer’s instructions. Cloned products were sequenced with the GenomeLab Dye Terminator Cycle Sequencing Kit and the automatic sequencer GenomeLab GeXP Genetic Analysis System (Beckman-Coulter, Pasadena, CA, USA). Plasmids were used in subsequent assays as positive controls. For the rest of subjects, the uncloned fragments were sequenced with their respective primers.

The HBV genome sequences obtained from HBsAg (-)/anti-HBc (+) patients were submitted to GenBank (www.ncbi.nlm.nih.gov/genebank) and the following accession numbers were assigned: KY564282-KY564304, KY564305-KY564310, KY762267-KY762285, KY807557-KY807561, KY595528-KY595536 and KY595538-KY595540.

**Real-time PCR**

Power SYBR Green PCR Master Mix (2X) (Applied Biosystems, Foster City CA, USA) or Maxima SYBR Green/ROX Master Mix (2X) (Thermo Scientific, MA, USA) were used to detect the HBV sequences by qualitative real-time PCR. Both Master Mix reagent kits were used in 10 μl reactions containing 150 to 200 nM of each primer (S1 Table) and 4 μl DNA. The amplification reaction was performed using the StepOne Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Cycling conditions were as follows: 10 min at 95˚C, and 40 cycles of 15s at 95˚C followed by 1 min at 54–60˚C. A melting curve was performed in each assay. The real time PCR reactions were made by triplicate or quadruplicate.

**Results**

**Effectiveness of HBV genome detection by 1R-PCR and nPCR**

The most effective primers (S1 Table) to detect HBV sequences by first round-PCR in the control group were those that amplified the products SPI: 7/10 (70%), followed by P and PC/C: 5/10 (50%), SP: 2/10 (20%), PX, PSI and PSII: 1/10 (10%). While the most effective primers for nPCR, amplified nSP1, nP and nPC/C: 10/10 (100%), followed by nSP3: 9/10 (90%), nPX: 7/10 (70%), nPSI: 5/10 (50%), nSP2: 4/10 (40%) and nPSII: 1/10 (10%). These results are summarized in Table 1.
Patients

Forty-five (38.8%) of the 116 HBsAg (-)/anti-HBc (+) evaluated patients met the inclusion criteria; 45.5% were female and 54.5% male, age range was 26–84 years old, average age was 57.5 years, 13.3% had been vaccinated against HBV, 6.6% were HBeAg (+) and 40% had a diagnosis of liver disease (S2 Table).

Efficacy of primers for the detection of the HBV genome in HBsAg (-)/anti-HBc (+) patients by nPCR

Serum samples of all the 45 HBsAg (-)/anti-HBc (+) patients were assayed in nPCR, using all the primer pairs shown in S1 Table. Twenty-nine (64.4%) of the 45 samples were positive for detection of at least two regions of the HBV genome (Table 2).

The most effective primer pairs to detect HBV sequences by nPCR were: nSP1s-nSP1a: 28/45 (62.2%), nSP3s-nSP3a: 26/45 (57.8%), nPC/Cs-nPC/Ca: 21/45 (46.7%) and nPs-nPa: 19/45 (42.2%); while the least effective primer pairs were nPXs-nPXa: 6/45 (13.3%), nPSIs-nPS1a: 4/45 (8.8%) and nPSIIs-PSIa: 1/45 (2.2%). The primer pair nSP2s-nSP2a did not generate amplicons in any case (Table 3). The effectiveness of primer pairs to obtain nPCR products was higher in the control group than in the HBsAg (-)/anti-HBc (+) patient group (Table 3).

Efficacy of primers for the detection of the HBV genome in HBsAg (-)/anti-HBc (+) patients by real time PCR

Of the 45 HBsAg (-)/anti-HBc (+) serum samples, 38 (84.4%) were positive for amplification of some region of the HBV genome with primers for real time PCR (S1 Table). The 6 products obtained (\textsuperscript{5}SP1, \textsuperscript{6}SP3, \textsuperscript{5}P, \textsuperscript{5}C, \textsuperscript{6}X and \textsuperscript{6}PSI) are shown in agarose gel (S1 Fig).

The most effective primer pairs to detect HBV products by real-time PCR were: SP1s-SP1a: 38/45 (84.4%), Cs-Ca: 35/45 (77.8%), SP3s-SP3a 32/45 (71.1%), Xs-Xa: 31/45 (68.8%) and Pols-Pola: 29/45 (64.4%); while the least effective pair was PolSIs-PolS1a: 11/45 (24.4%) (Table 4).
Table 2. Detection of HBV DNA products by nested and real-time PCR in a group of HBsAg (-)/anti-HBc (+) patients from Puebla, México.

| Patients | nSP1 | "SP1 | nSP3 | "SP3 | nP | "P | nPX | "X | nPC/C | "C | nPSI | "PSI | nPSII | GT | OBI |
|----------|------|------|------|------|----|----|-----|----|-------|----|-------|------|-------|----|-----|
| 1        | nD^5 | "D   | nD   | "D   | nD  | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 2        | nD^5 | "D   | nD   | "D   | nD  | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 3        | nD^5 | "D   | nD   | "D   | nD  | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 4        | nD   | "D   | -    | "D   | -   | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 5        | nD   | "D   | nD   | "D   | nD  | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 6        | nD^5 | "D   | nD   | "D   | nD  | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 7        | nD^5 | "D   | nD   | "D   | nD  | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 8        | nD^5 | "D   | nD   | "D   | nD  | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 9        | nD   | "D   | nD   | "D   | nD  | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 10       | nD^5 | "D   | nD   | "D   | nD  | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 11       | nD^5 | "D   | -    | "D   | nD^5 | -  | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 12       | nD   | "D   | nD^5 | "D   | -   | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 13       | nD^5 | "D   | nD^5 | "D   | -   | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 14       | nD^5 | "D   | nD   | "D   | nD  | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 15       | nD^5 | "D   | nD   | "D   | nD  | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 16       | nD^5 | "D   | nD   | "D   | nD  | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 17       | nD^5 | "D   | nD   | "D   | nD  | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 18       | nD^5 | "D   | nD^5 | "D   | -   | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 19       | nD   | "D   | nD   | "D   | nD  | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 20       | nD^5 | "D   | nD^5 | "D   | -   | "D | -    | "D | nD^5  | "D | nD^5 | "D   | -    | H   | Yes |
| 21       | nD^5 | "D   | nD   | "D   | -   | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 22       | nD^5 | "D   | nD   | "D   | -   | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 23       | nD^5 | "D   | nD   | "D   | -   | "D | -    | "D | nD^5  | "D | -    | "D   | -    | H   | Yes |
| 24       | nD^5 | "D   | nD   | "D   | nD^5 | "D | -   | "D | -    | "D | -    | "D   | -    | H   | Yes |
| 25       | nD^5 | "D   | nD   | "D   | nD^5 | "D | -   | "D | nD^5  | "D | nD^5 | "D   | -    | H   | Yes |
| 26       | nD^5 | "D   | nD   | "D   | -   | "D | -    | "D | nD^5  | "D | nD^5 | "D   | -    | H   | Yes |
| 27       | nD^5 | "D   | nD   | "D   | -   | "D | -    | "D | nD^5  | "D | nD^5 | "D   | -    | H   | Yes |
| 28       | nD^5 | "D   | nD   | "D   | nD  | "D | -    | "D | nD^5  | "D | nD  | "D   | -    | H   | Yes |
| 29       | -    | "D   | -    | "D   | -   | "D | -    | "D | nD^5  | "D | nD  | "D   | nD^5 | H   | Yes |
| 30       | -    | "D   | -    | "D   | -   | "D | -    | "D | nD^5  | "D | nD  | "D   | nD^5 | H   | Yes |
| 31       | -    | "D   | -    | "D   | -   | "D | -    | "D | nD^5  | "D | nD  | "D   | nD^5 | H   | Yes |
| 32       | -    | "D   | -    | "D   | -   | "D | -    | "D | nD^5  | "D | nD  | "D   | nD^5 | H   | Yes |
| 33       | -    | "D   | -    | "D   | -   | "D | -    | "D | nD^5  | "D | nD  | "D   | nD^5 | H   | Yes |
| 34       | -    | "D   | -    | "D   | -   | "D | -    | "D | nD^5  | "D | nD  | "D   | nD^5 | H   | Yes |
| 35       | -    | "D   | -    | "D   | -   | "D | -    | "D | nD^5  | "D | nD  | "D   | nD^5 | H   | Yes |
| 36–38    | -    | "D   | -    | "D   | -   | "D | -    | "D | nD^5  | "D | nD  | "D   | nD^5 | NG  | No  |
| 39–45    | -    | "D   | -    | "D   | -   | "D | -    | "D | nD^5  | "D | nD  | "D   | nD^5 | NG  | No  |

n = nested PCR, " = real time PCR; nD^5 or "D^5 = HBV DNA detected and sequenced (concentration > 15ng/μl), nD or "D = HBVDNA detected but not sequenced due to low concentration,— = HBV DNA not detected in this region,
* = genotyped with the real-time PCR product, NG = Not genotyped, OBI = Occult hepatitis B virus infection.

https://doi.org/10.1371/journal.pone.0205356.t002

Patients who met the definition of occult hepatitis B virus infection

Of the initial 45 probable occult hepatitis B patients that were HBsAg (-)/anti-HBc (+), 34 (75.5%) had HBV detected by PCR in at least three different viral genomic regions and thus met the criteria to be considered with occult hepatitis B virus infection. Of them, 29 (64.4%) were detected both by nPCR and real-time PCR, while 5 more (11.1%) were detected by real-time...
PCR only (Table 2). The sequenced products of OBI patients and control group were analyzed and 100% of individuals in both groups had genotype H (Tables 1 and 2). Four patients were DNA HBV positive by real time PCR but were not considered as OBI because one of them was positive for three different segments by real-time PCR, but none was successfully sequenced; the other three patients were positive in only two distinct real-time PCR assays and none could not be sequenced (Table 2). Seven samples were negative in nPCR and real time PCR and were then considered not to be infected by HBV (Table 2). The effectiveness of primer pairs to detect the HBV DNA in different types of samples were arranged from highest to lowest and summarized in Tables 3 and 4.

### Discussion

HBV virions present in the serum of infected individuals have an unusually structured genome, composed of a partially double-stranded, relaxed circular DNA (rcDNA), with none

| Primer pairs | HBV genome region ORF | Control group n (%) | HBsAg (-)/Anti-HBc (+) patients n (%) |
|--------------|-----------------------|----------------------|--------------------------------------|
| nSP1s        | PreS2/P                | 10 (100)             | 28 (62.2)                            |
| nSP1a        | S/P                   |                       |                                      |
| nSP3s        | PreS2/P               | 9 (90)               | 26 (57.7)                            |
| nSP3a        | S/P                   |                       |                                      |
| nPC/Cs       | X/PreC                | 10 (100)             | 21 (46.6)                            |
| nPC/Ca       | C                     |                       |                                      |
| nPs          | P                     | 10 (100)             | 19 (42.2)                            |
| nPa          | P/X                   |                       |                                      |
| nPXs         | P/X/                    | 7 (70)               | 6 (13.3)                             |
| nPXa         | X                     |                       |                                      |
| nPSIs        | C/P                   | 5 (50)               | 3 (8.8)                              |
| nPSIa        | P                     |                       |                                      |
| nPSIIs       | P/PreS2/P             | 1(10)                | 1 (2.2)                              |
| nPSIa        |                        |                       |                                      |
| nSP2s        | S/P                   | 4 (40)               | 0 (0.0)                              |
| nSP2a        | P                     |                       |                                      |

https://doi.org/10.1371/journal.pone.0205356.t003

Table 4. Effectiveness of primer pairs to detect HBV DNA in HBsAg (-)/anti-HBc (+) patients from Puebla, Mexico by real-time PCR.

| Primer pair | HBV genome region ORF | HBsAg (-)/Anti-HBc (+) Patients n (%) | Rate of nPCR (+) in nPCR (-) samples n_{nPCR(+)} / n_{nPCR(-)} (%) | Rate of in nPCR (+) in nPCR (+) samples n_{nPCR(+)} / n_{nPCR(+)} (%) |
|-------------|-----------------------|--------------------------------------|-------------------------------------------------|------------------------------------------------------------------|
| SP1s        | PreS2/P               | 38 (84.4)                           | 10 /17 (58.8)                                    | 0/28 (0.0)                                                        |
| SP1a        | S/P                   |                       |                                                  |                                                                  |
| Cs          | C                     | 35 (77.8)                           | 14/24 (58.3)                                     | 0/21 (0.0)                                                        |
| Ca          | C                     |                       |                                                  |                                                                  |
| SP3s        | S/P                   | 32 (71.1)                           | 7/19 (36.8)                                      | 1/26 (3.8)                                                        |
| SP3a        | S/P                   |                       |                                                  |                                                                  |
| Xs          | X                     | 31 (68.8)                           | 26/39 (69.2)                                     | 1/6 (16.6)                                                        |
| Xa          | X                     |                       |                                                  |                                                                  |
| Pols        | P                     | 29 (64.4)                           | 12/26 (38.4)                                     | 2/19 (10.5)                                                       |
| Pola        | P                     |                       |                                                  |                                                                  |
| PolsIs      | P                     | 11 (24.4)                           | 7/41 (17.0)                                      | 0/4 (0.0)                                                         |
| PolsIa      | P                     |                       |                                                  |                                                                  |

https://doi.org/10.1371/journal.pone.0205356.t004
of the strands covalently closed [15] and a gap in the minus strand [16]. In contrast, inside infected cells the stable form of the viral genome is a covalently closed circular DNA (cccDNA) that forms a mini-chromosome in the cell nucleus [17]. This cccDNA is found in serum in much smaller quantities than rcDNA adding complexity to the detection of the HBV genome in human serum, as not all genome regions are equally accessible in rcDNA.

To detect OBI efficiently, primers need to be designed for highly conserved sections of the HBV genotypes that circulate in each geographical region and used in highly sensitive and specific methods like nPCR or real-time PCR [3, 18]. The primers for this study were designed using the complete HBV genome sequences reported in GenBank, mainly from Mexico. The most effective primer pairs to identify the HBV genome in our HBsAg (-)/anti-HBc (+) patients, hybridized at the PreS2/P, S/P regions and were pairs nSP1s-nSP1a and nSP3s-nSP3a (Table 3). Recently, primers close to this region have been used to detect OBI in genotypes different than H [19–22]. We also obtained satisfactory results with primers located at the X/PreC and C regions (nPC/Cs-nPC/Ca) (Table 3), flanking the X/PreC region (nt1753 to nt1777), which is associated with substitutions and deletions found in OBI patients in other genotypes [23]. These primers also flank the gap region close to direct repeat 1 (DR1). Primers close to this region have been used previously to detect OBI [19, 24–25].

Primers that hybridize at the P/X region (nPXs-nPXa) were much less effective to produce PCR amplicons (Table 3), probably because their target sequence is within direct repeat 2 (DR2), between nt 1590 and nt 1600, very close to the single-stranded region at the 5’end of the rcDNA [15–16]. Accordingly, the nPs-nPa primers that target a similar area in the P/X region but do not include the DR2, had a better efficacy, amplifying 100% of controls and 42.2% of patients (Table 3).

PCR products with the nPSIs-nPSIa pair were found at a relatively low frequency in patients. By nested PCR, these primers produced an amplicon in 50% of controls but only 8.8% patients (Table 3). These primers hybridize at the P gene, which may be difficult to copy in its rcDNA form due to limited access. In a similar case, the nSP2s-nSP2a primers were unable to detect the HBV genome in HBsAg (-)/anti-HBc (+) patients but detected 40% of control individuals (Table 3). Sequence variation in these regions or low HBV DNA in patient samples could be involved in the different detection rate between controls and patients.

The nPSIIIs-PSIa primers had low efficiency in both controls and patients, with only one positive sample in each group (Table 3). The PSIa primer is located at the PreS1 region, where a deletion at nt2983-3201 has been reported in OBI patients [23, 26–27] and deletions have been reported in patients in different stages of the HBV infection [28]. As expected, more patients were detected by real-time PCR than by nPCR (Table 2). More than half of nPCR negative samples were detected as positive using real-time PCR primers targeted to the PreS2/P, S/P and C regions (Table 4). However, the most effective real-time PCR primers to detect HBV genome in negative nPCR samples were those designed for the X region, where there is no overlap with other ORFs (Table 4). In summary, the most effective primers to detect OBI in HBsAg (-)/anti-HBc (+) patients, hybridized at the PreS2/P, S/P, C and X regions, which harbor the most conserved sequences.

Infrequent negative results for real-time PCR in patients that had positive nPCRs were found for primer pairs Xs-Xa in 16.6% of samples, Pols-Pola in 10.5% and SP3s-SP3a in 3.8% (Table 2). These false negative results in real time PCR were detected thanks to the simultaneous use of two PCR techniques and have not been reported before.

Under identical conditions, the Power SYBR Green PCR Master Mix was able to detect the HBV genome in more samples than the Maxima SYBR Green/ROX Master Mix; this observed in particular for primer pairs Xs-Xa and SP3s-SP3a in 50% and 20% respectively, of the “PCR (+) samples that were nPCR (-) (Table 4).
Some patients in the present study had a history of anti-HBV vaccination; however vaccination was less frequent in individuals ultimately classified as OBI (5.8% vs 36%). Accordingly, a recent study showed that OBI was more frequent in unvaccinated Mexican children [29]. In turn, HBeAg was detected in only 8.8% of the patients, consistent with a recent study, which proposed that OBI with positive HBeAg is rare and associated with active HBV replication [30]. HBeAg has been previously detected in Mexican blood donors with OBI at a low frequency (4%) [31].

A high percentage of HBsAg (-)/anti-HBc (+) of patients with (87.5%) and without (66.6%) liver disease were detected as OBI in our study, similar to previously reported in [3] and [19], respectively. In Mexico, OBI has been detected in 14.2% of native population (Nahuas and Huichol) only reactive to anti-HBc and without a diagnosis of liver disease [32]. In Mexican blood donors it has been detected ranging from 11 to 17.3% [31,33], and in HIV-1 patients in 49% [24]. However, more studies on this health problem are needed to determine the true impact of OBI in the Mexican population. The strategy and sets of primers described here can improve HBV and OBI detection protocols.

Conclusions
In this study, we have proposed and tested sets of primers for the detection of the HBV genome by nPCR and real-time PCR in probable OBI patients. Primers designed for the PreS2/P, S/P, C and X regions were able to confirm 75.5% of probable OBI cases.

Supporting information
S1 Fig. Example of the six real time PCR products obtained with the primers listed in S1 Table.
(DOCX)
S1 Table. Primers to detect hepatitis B virus in serum of anti-HBc (+)/HBsAg (-) patients by PCR (first round), nested PCR, and real time PCR.
(DOCX)
S2 Table. Data of anti-HBc (+)/HBsAg (-) patients from Puebla, México.
(DOCX)
S3 Table. Sequenced rtPCR products that were too short to upload to GenBank and their viral genotype as identified through a GenBank blast.
(DOCX)

Acknowledgments
To Dr. Tomas Vargas Maldonado (†) for data and tests performed to blood donors. Dr. Julio Reyes-Leyva has a research fellowship from Fundación IMSS A.C.

Author Contributions
Conceputalization: Francisca Sosa-Jurado, Julio Reyes-Leyva, Verónica Vallejo-Ruiz, Gerardo Santos-Lopez.

Data curation: Francisca Sosa-Jurado, Daniel Meléndez-Mena, Belinda Guzmán-Flores, Miguel A. Mendoza-Torres, Roberto Barcenas-Villalobos, Luis Márquez-Dominguez, Paulina Cortés-Hernández.
Formal analysis: Francisca Sosa-Jurado, Daniel Meléndez-Mena, Nora H. Rosas-Murrieta, Miguel A. Mendoza-Torres, Gerardo Santos-López.

Funding acquisition: Francisca Sosa-Jurado, Julio Reyes-Leyva.

Investigation: Francisca Sosa-Jurado, Daniel Meléndez-Mena, Belinda Guzmán-Flores, Roberto Barcenas-Villalobos.

Methodology: Francisca Sosa-Jurado, Nora H. Rosas-Murrieta, Luis Márquez-Domínguez, Gerardo Santos-López.

Project administration: Francisca Sosa-Jurado.

Resources: Francisca Sosa-Jurado.

Validation: Daniel Meléndez-Mena, Belinda Guzmán-Flores.

Writing – original draft: Francisca Sosa-Jurado, Paulina Cortés-Hernández, Verónica Vallejo-Ruíz, Gerardo Santos-López.

Writing – review & editing: Francisca Sosa-Jurado, Paulina Cortés-Hernández, Gerardo Santos-López.

References

1. Chang MH. Prevention of hepatitis B virus infection and liver cancer. Recent Results Cancer Res. 2014; 193:75–95. https://doi.org/10.1007/978-3-642-38965-8_5 PMID: 24008294
2. Guidelines on hepatitis B and C testing. World Health Organization. apps.who.int/iris/bitstream/10665/254621/1/9789241549981-eng.pdf Accessed February 2017.
3. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008; 49:652–7. https://doi.org/10.1016/j.jhep.2008.07.014 PMID: 18715666
4. De la Fuente RA, Gutiérrez ML, García-Samaniego J, Fernández-Rodríguez C, Lledó JL, Castellano G. Pathogenesis of occult chronic hepatitis B virus infection. World J Gastroenterol. 2011; 17:1543–8. https://doi.org/10.3748/wjg.v17.i12 PMID: 21472118
5. Echevarría JM, Avellón A. Improved detection of natural hepatitis B virus surface antigen (HBsAg) variants by a new version of the VITROS HBsAg assay. J Med Virol. 2008; 80:598–602. https://doi.org/10.1002/jmv.21146 PMID: 18297712
6. Lou SC, Pearce SK, Lukaszewska TX, Taylor RE, Williams GT, Leary TP. An improved Abbott ARCHITECT assay for the detection of hepatitis B virus surface antigen (HBsAg). J ClinVirol. 2011; 51:59–63.
7. Krawczyk A, Hintze C, Ackermann J, Goitowski B, Trippler M, Grüner N, et al. Clinical performance of the novel DiaSorin LIAISON® XL murex: HBsAg Quant, HCV-Ab, HIV-Ab/Ag assays. J ClinVirol. 2014; 59:44–9.
8. El Chaar M, Candotti D, Crowther RA, Allain JP. Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology. 2010; 52:1600–10. https://doi.org/10.1002/hep.23886 PMID: 20815025
9. Jaramillo CM, Navas MC. [Escape mutants of hepatitis B virus]. Rev Chilena Infectol. 2015; 32:190–7. https://doi.org/10.4067/S0716-10182015000300008 PMID: 26065452
10. Almeida RW, Mello FCDA, Menegoy IV, Santo MPDE, Ginuino CF, Sousa PSF, et al. Detection and molecular characterisation of a diagnosis escape variant associated with occult hepatitis B virus in Brazil. Mem Inst Oswaldo Cruz. 2017; 112:485–491 https://doi.org/10.1590/0074-02760160477 PMID: 28591309
11. Squadrito G, Spinella R, Raimondo G. The clinical significance of occult HBV infection. Ann Gastroenterol. 2014; 27:15–19. PMID: 24714731
12. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al. Primer3 new capabilities and interfaces. Nucleic Acids Res. 2012; 40:e115. https://doi.org/10.1093/nar/gks596 PMID: 22730293
13. Owczarzy R, Tataurov AV, Wu Y, Manthey JA, McQuisten KA, Almabrazil HG, et al. IDT SciTools: A suite for analysis and design of nucleic acid oligomers. Nucleic Acids Res. 2008; 36:W163–W169. https://doi.org/10.1093/nar/gkn198 PMID: 18440976
14. Sanyal D, Kudesia G, Corbitt G. Comparison of ultracentrifugation and polyethylene glycol precipitation for concentration of hepatitis B virus (HBV) DNA for molecular hybridisation tests and the relationship of...
15. Schreiner S, Nassal M. A role for the host DNA damage response in hepatitis B virus cccDNA formation and beyond? Viruses. 2017; 9:125.

16. Minosse C, Coen S, Comandini UV, Lionetti R, Montalbano M, Cerilli S, et al. Simple and reliable method to quantify the hepatitis B viral load and replicative capacity in liver tissue and blood leukocytes. Hepat Mon. 2016; 16:e28751. https://doi.org/10.5812/hepatomon.28751 PMID: 27882060

17. Seeger C and Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015; 479–480:672–686. https://doi.org/10.1016/j.virol.2015.02.031 PMID: 25759099

18. Raimondo G, Pollicino T, Romano L, Zanetti AR. A 2010 update on occult hepatitis B infection. Pathol Biol (Paris). 2010; 58:254–7.

19. Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol. 2008; 48:743–6. https://doi.org/10.1016/j.jhep.2008.01.023 PMID: 18314221

20. Kim MH, Kang SY, Lee WI. Occult HBV among anti-HBc alone: Mutation analysis of an HBV surface gene and Pre-S Gene. Yonsei Med J. 2017; 58:557–563. https://doi.org/10.3349/ymj.2017.58.3.557 PMID: 28332361

21. Taha SE, El-Hady SA, Ahmed TM, Ahmed IZ. Detection of occult HBV infection by nested PCR assay among chronic hepatitis C patients with and without hepatocellular carcinoma. Egypt J Med Hum Genet. 2013; 14:353–360

22. Gachara G, Magoro T, Mavhandu L, Lum E, Kimbi HK, Ndip RN, et al. Characterization of occult hepatitis B virus infection among HIV positive patients in Cameroon. AIDS Res Ther. 2017; 14:11. https://doi.org/10.1186/s12981-017-0136-0 PMID: 28270215

23. Zhu HL, Li X, Zhang ZH. Genetic variation of occult hepatitis B virus infection. World J Gastroenterol. 2016; 22:3531–46. https://doi.org/10.3748/wjg.v22.i13.3531 PMID: 27053845

24. Alvarez MMT, Maldonado RA, Rojas MO, Torres IR, Gutierrez EF, Vazquez RG, et al. Occult hepatitis B virus infection among Mexican human immunodeficiency virus-1-infected patients. World J Gastroenterol. 2014; 20:13530–7. https://doi.org/10.3748/wjg.v20.i37.13530 PMID: 25309083

25. Hassan ZK, Hafez MM, Mansor TM, Zekri AR. Occult HBV infection among Egyptian hepatocellular carcinoma patients. Virol J. 2011; 8:90. https://doi.org/10.1186/1743-422X-8-90 PMID: 21371325

26. Kim H, Lee SA, Lee SH, Kim BJ. Naturally occurring mutations in large surface genes related to occult infection of hepatitis B virus genotype C. PLoS ONE. 2013; 8:e54486. https://doi.org/10.1371/journal.pone.0054486 PMID: 23349904

27. Kim H, Kim BJ. Association of preS/S Mutations with Occult Hepatitis B Virus (HBV) Infection in South Korea: Transmission Potential of Distinct Occult HBV Variants. Int J Mol Sci. 2015; 16:13595–13609. https://doi.org/10.3390/ijms160613595 PMID: 26034041

28. Malve B, Eschlimann M, Galgey S, Fenaux H, Zoulim F, Goehring er F, et al. Impact of deletions and mutations in Hepatitis B virus envelope proteins on serological profile and clinical evolution. Virus Res. 2017; 238:141–147. https://doi.org/10.1016/j.virusres.2017.06.028 PMID: 28673869

29. Escobedo MG, Panduro A, Fierro NA, Roman S. High prevalence of occult hepatitis B virus genotype H infection among children with clinical hepatitis in west Mexico. Mem Inst Oswaldo Cruz. 2014; 109:728–737. https://doi.org/10.1590/0074-0276140058 PMID: 25099333

30. Han Z, Liu Y, Pan J, Bi Y, Liu J, Zhou YH. Occult hepatitis B virus infection with positive hepatitis B e antigen. Clin Chim Acta. 2015; 438:266–8. https://doi.org/10.1016/j.cca.2014.09.007 PMID: 25218700

31. Garcia MBM, Ventura ZLP. Molecular and serological characterization of occult hepatitis B infection in blood donors from Mexico. Ann Hepatol. 2011; 10:133–41. PMID: 21502674

32. Roman S, Tanaka Y, Khan A, Kurbanov F, Kato H, Mizokami M et al. Occult hepatitis B in the genotype H-infected Nahuas and Huichol native Mexican population. J Med Virol. 2010; 82:1527–36 https://doi.org/10.1002/jmv.21846 PMID: 20648606

33. Sosa JF, Rosas MNH, Guzman FB, Perez ZC, Sanchez TAP, Ramirez RL, et al. Prevalence of serologic hepatitis B markers in blood donors from Puebla, Mexico: The association of relatively high levels of anti-Core antibodies with the detection of surface antigen and genomic DNA. Hepat Mon. 2016; 16:e36942. https://doi.org/10.5812/hepatomon.36942 PMID: 27630726